Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Seres Therapeutics (NASDAQ:MCRB) but has reduced the price target from $10 to $9. This adjustment reflects a revised valuation of the company's prospects.
January 16, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Seres Therapeutics' Outperform rating is maintained by Oppenheimer, but the price target is lowered from $10 to $9, indicating a slightly less optimistic but still positive view on the stock's future performance.
While the reduction in price target could suggest a more conservative outlook on Seres Therapeutics' future performance, the maintenance of an Outperform rating indicates that Oppenheimer still has a positive view on the stock. This mixed signal might lead to a neutral short-term impact on the stock price as investors digest both the positive rating and the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100